ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Jennifer Litton on the Phase III BETH Trial

Jennifer Litton, MD
Published: Wednesday, Dec 11, 2013



Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial, which studied chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus bevacizumab in patients with HER2+ breast cancer. The results of this trial were presented by Dennis J. Slamon, MD, PhD, at the San Antonio Breast Cancer Symposium on Wednesday, December 11.

Litton says the BETH trial looked at whether or not bevacizumab added benefit to patients with HER2+ breast cancer who received chemotherapy and trastuzumab. Slamon’s presentation showed that bevacizumab did not add any significant benefit, Litton says, but it did add the expected toxicity of high blood pressure, proteinuria and blood clotting.

Litton says she would not recommend giving bevacizumab to this group of patients.

<<< View more from the 2013 SABCS Meeting



Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial, which studied chemotherapy plus trastuzumab versus chemotherapy plus trastuzumab plus bevacizumab in patients with HER2+ breast cancer. The results of this trial were presented by Dennis J. Slamon, MD, PhD, at the San Antonio Breast Cancer Symposium on Wednesday, December 11.

Litton says the BETH trial looked at whether or not bevacizumab added benefit to patients with HER2+ breast cancer who received chemotherapy and trastuzumab. Slamon’s presentation showed that bevacizumab did not add any significant benefit, Litton says, but it did add the expected toxicity of high blood pressure, proteinuria and blood clotting.

Litton says she would not recommend giving bevacizumab to this group of patients.

<<< View more from the 2013 SABCS Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x